Biotech Stocks: AI Beats the S&P500 by 48.72%


  • The highest average return is 48.72% for the Top 5 Signals on a 1-year time horizon
  • The average return across all signal and horizon groups is positive while the S&P500 has a negative performance for the same period of time
  • Predictions reach up to a 87% hit ratio regardless of economic conditions

Read Full Report

The Coronavirus Package Content

The main focus of the Coronavirus package is to cover the assets that may be affected by the coronavirus with the biggest financial exposures and it includes assets such as gold and relevant commodities, biotech companies’ stocks, pharmaceutical companies’ stocks, semiconductors, and technological sectors stocks and more. The Coronavirus package contents 142 tickers on December 2nd, 2021

OCGN Stock Forecast: Covaxin’s FDA Status Marks the Future

This OCGN stock forecast article was written by Maria Grishaev, Analyst at I Know First.

Executive Summary

  • Ocugen had a good year in 2020. The stock price went up by 239.52% despite the COVID-19 pandemic.
  • A deal to commercialize Covaxin in the U.S. was signed with Bharat Biotech can have an impact on revenue if the FDA will give the vaccine an Emergency Use Authorization.
  • Quantitative analysis results indicate bullish signals after stock price topped out the moving average line.
  • OCGN deserves a one-year target price of $13, representing potential revenue growth.

New forecasting serviceRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Coronavirus Stock Market: How To Profit With Medical Advancements

This article was written by Gabriel Plat, a Financial Analyst at I Know First.


  • The COVID-19 pandemic left an opportunity to companies profit by developing a treatment and a vaccine;
  • Gilead and CytoDyn already started clinical trials with its drugs;
  • Partnering with other companies is also a strategy to reach the treatment faster than the competition;
  • These companies' stocks can be a huge opportunity to profit in the near future.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Winning Stock Forecast: RGEN Gains 15.8% in 14 Days

(source :

Over the period of June 16th to June 30th, Repligen Corporation (RGEN) stocks prices jumped by 15.8% in 14 days in agreement with the bullish I Know First forecast. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics

Read More

Winning Stock Forecast: Celldex Therapeutics (CLDX) Remarkable Return of 130.93% Over 1 Month

CLDX Winning Stock Forecast

Source: pixnio

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a bio-pharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Source: flickr

Celldex’s pipeline is comprised of immunotherapies and other targeted biologics. Their drug candidates are derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. They are aimed at addressing market opportunities for which they believe current therapies are inadequate or non-existent.

Over the period from 3rd January to 3rd February CLDX saw a stock rise of 130.93% this was the highest performing stock over that period from the BioTech stocks I Know First package.

Over the course of the 2018, the stock reached a high of $2.86 and a low of $0.18, which as a result has the increased attention of keen investors who are following the progress of the asset as it gets closer to a significant historic high price or low value. The stock currently stands at $0.59.

Current I Know First subscribers received a bullish CLDX forecast on 3rd January. With a signal of 1.82 for the month-long time frame.

The graph below shows this remarkable return for CLDX stock over this time period in-line with the I Know First forecast:

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

DVAX Stock Forecast: Table Is Being Set – Revenue Growth Is On The Way


The article was written by Amber Zhou, a Financial Analyst at I Know First.

DVAX Stock Forecast

“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.




  • Competitive Edge and Huge Market Potential from Heplisav-B®
  • Market Doubts about Trial Data of Immuno-Oncology Platform
  • Strong Cash Position from Debt Financing
  • Current I Know First Bullish Forecast For DVAX

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here